Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
PL 017Cat. No. 2024 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
Biological Activity
Selective μ opioid receptor agonist (IC50 values are 5.5 and > 10000 nM for inhibition of 125I-FK 33,824 and 125I-DADLE binding to μ and δ sites respectively). Produces naloxone-reversible analgesia, catalepsy and hyperthermia following central administration in rats in vivo.Technical Data
M.Wt:(Modifications:Phe-3 = N-methyl-Phe, Pro-4 = C-terminal amide)
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
References
Chang et al (1983) Potent morphiceptin analogs: structure activity relationships and morphine-like activities. J.Pharmacol.Exp.Ther. 227 403. PMID: 6313901.
Meyer and Meyer (1993) Behavioral effects of the μ-opioid peptide agonists DAMGO, DALDA and PL017 on locomotor activities. Pharmacol.Biochem.Behav. 46 391. PMID: 8265694.
Xin et al (1997) Body temperature and analgesic effects of selective mu and kappa opioid receptor agonists microdialyzed into rat brain. J.Pharmacol.Exp.Ther. 281 499. PMID: 9103537.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: PL 017, supplier, mu, m, opioid, agonists, analgesia, catalepsy, hyperthermia, PL017, potent, selective
Quick Order
Find multiple products by catalog number
Pain Research Guide
Reserve your free copy
Highlights over 280 products for Pain research. Reserve copy
Appetite Modulation
Written by Sonia A. Tucci, Lynsay Kobelis & Tim Kirkham. Request a copy or view PDF today.
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.